Monoclonal antibody in the treatment of multiple myeloma

iStock_000025815091_Full (1)Multiple myeloma (MM) is considered to be an incurable disease. However, with the release of Daratumumab by the US FDA in November 2015 there is a real hope for patients suffering from this chronic disease. The drug was registered for patients with MM in whom the use of elementary line treatment, with the proteasome inhibitor (PI) and an immunomodulating agent, was ineffective.

Read full text »